Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03836053 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
23
Enrollment
INDUSTRY
Sponsor class

Stopped Amgen re-evaluated the portfolio and decided to discontinue clinical development activities for AMG 420.

Conditions

Interventions

Sponsor

Amgen